# DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

Source: https://onco.cc/trials/nct02197169/  
OnCo record `nct02197169` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.

## Summary

DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors is a phase 1 interventional study registered as NCT02197169 by DNAtrix, Inc., with 37 participants enrolled, started 2014-09-11. Conditions recorded: Glioblastoma or Gliosarcoma. Interventions recorded: Single intratumoral injection of DNX-2401 and Interferon-gamma.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02197169
- Phase: 1
- Setting: A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)
- Sponsor: DNAtrix, Inc.
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT02197169: https://clinicaltrials.gov/study/NCT02197169

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct02197169.json